Trial reportJAMA network open2025
Open-Label Placebos as Adjunct for the Preventive Treatment of Migraine: A Randomized Clinical Trial.
Trial report in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeting individual pain catastrophizing to reduce migraine-related disability: a randomized controlled proof-of-concept trial using an online CBT intervention.Scientific reports · 2026Trial
- Review
- Article
- A victim of its own progress: why the success of modern therapeutics forces a re-evaluation of placebo-controlled trials in migraine prevention.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Placebo effects contribute substantially to the therapeutic success of many treatments, particularly in pain-related conditions. Open-label placebos (OLPs) offer an ethically acceptable approach to harness this potential without deception. Objective: To evaluate the efficacy of a 3-month OLP regimen in reducing headache and migraine days and improving migraine-related outcomes, including medication use, disability, and quality of life, in patients with migraine. Design, Setting, and Patients: This controlled, bicenter, parallel-group randomized clinical trial, with a 3-month treatment phase, enrolled adults with episodic or chronic migraine between November 9, 2020, and November 1, 2022. The trial was conducted at 2 tertiary headache centers in Germany (University Medicine Essen and Headache Center Frankfurt). Interventions: Participants received OLPs plus treatment as usual (TAU) or TAU alone. OLPs were administered twice daily for 3 months. Main Outcomes and Measures: The preregistered primary outcome was the change in monthly headache days from a baseline to a test period after 3 months. Secondary outcomes included patient-reported quality of life assessed using the 12-Item Short-Form Health Survey physical component summary, pain-related disability assessed using the Pain Disability Index and Headache Impact Test, and global improvement. Results: Of the 120 patients (median age, 34.2 years; 95% CI, 29.8-39.3 years; 103 [86%] female), 102 (85%) had episodic migraine, and 18 (15%) had chronic migraine. All participants completed the study. Headache days did not significantly decrease in the OLP group compared with TAU. Similarly, there was no difference in the number of migraine days, pain intensity, days of rescue medication, and the 50% responder rate. However, OLP-treated patients reported improved quality of life (β = 4.25; 95% CI, 1.33-7.17; d = 0.47; P = .01), reduced pain-related disability (Pain Disability Index: β = -5.96; 95% CI, -9.01 to -2.92; d = 0.53; P < .001; Headache Impact Test 6: β = -1.88; 95% CI, -3.28 to -0.48; d = 0.35; P = .02), and higher global improvement (χ2 = 14.16; P = .01) compared with TAU patients. Conclusions and Relevance: In this randomized clinical trial, OLP treatment did not reduce headache frequency but was associated with improvements in quality of life and pain-related disability. Future research should clarify the mechanisms underlying these effects and determine their potential supportive role in migraine care for selected patients. Trial Registration: drks.de identifier: DRKS00021259.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.